435 related articles for article (PubMed ID: 25106761)
1. Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial.
Wijns W; Steg PG; Mauri L; Kurowski V; Parikh K; Gao R; Bode C; Greenwood JP; Lipsic E; Alamgir F; Rademaker-Havinga T; Boersma E; Radke P; van Leeuwen F; Camenzind E;
Eur Heart J; 2014 Oct; 35(40):2812-20. PubMed ID: 25106761
[TBL] [Abstract][Full Text] [Related]
2. Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
Camenzind E; Boersma E; Wijns W; Mauri L; Rademaker-Havinga T; Ordoubadi FF; Suttorp MJ; Al Kurdi M; Steg PG;
Eur Heart J; 2014 Aug; 35(29):1932-48. PubMed ID: 24627416
[TBL] [Abstract][Full Text] [Related]
3. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
4. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
5. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial.
Camenzind E; Wijns W; Mauri L; Kurowski V; Parikh K; Gao R; Bode C; Greenwood JP; Boersma E; Vranckx P; McFadden E; Serruys PW; O'Neil WW; Jorissen B; Van Leeuwen F; Steg PG;
Lancet; 2012 Oct; 380(9851):1396-405. PubMed ID: 22951082
[TBL] [Abstract][Full Text] [Related]
6. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Eisenstein EL; Leon MB; Kandzari DE; Mauri L; Edwards R; Kong DF; Cowper PA; Anstrom KJ;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1199-207. PubMed ID: 20129546
[TBL] [Abstract][Full Text] [Related]
8. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
Hofma SH; Brouwer J; Velders MA; van't Hof AW; Smits PC; Queré M; de Vries CJ; van Boven AJ
J Am Coll Cardiol; 2012 Jul; 60(5):381-7. PubMed ID: 22835668
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Short- and Long-Term Cardiac Mortality in Early Versus Late Stent Thrombosis (from Pooled PROTECT Trials).
Secemsky EA; Matteau A; Yeh RW; Steg PG; Camenzind E; Wijns W; McFadden E; Mauri L;
Am J Cardiol; 2015 Jun; 115(12):1678-84. PubMed ID: 25910523
[TBL] [Abstract][Full Text] [Related]
10. 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents.
Maeng M; Tilsted HH; Jensen LO; Kaltoft A; Kelbæk H; Abildgaard U; Villadsen AB; Krusell LR; Ravkilde J; Hansen KN; Christiansen EH; Aarøe J; Jensen JS; Kristensen SD; Bøtker HE; Madsen M; Thayssen P; Sørensen HT; Thuesen L; Lassen JF
JACC Cardiovasc Interv; 2012 Aug; 5(8):812-8. PubMed ID: 22917452
[TBL] [Abstract][Full Text] [Related]
11. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
[TBL] [Abstract][Full Text] [Related]
12. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
[TBL] [Abstract][Full Text] [Related]
13. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).
Valgimigli M; Borghesi M; Tebaldi M; Vranckx P; Parrinello G; Ferrari R;
Eur Heart J; 2013 Mar; 34(12):909-19. PubMed ID: 23315904
[TBL] [Abstract][Full Text] [Related]
14. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.
Byrne RA; Kastrati A; Tiroch K; Schulz S; Pache J; Pinieck S; Massberg S; Seyfarth M; Laugwitz KL; Birkmeier KA; Schömig A; Mehilli J;
J Am Coll Cardiol; 2010 Jun; 55(23):2536-43. PubMed ID: 20417052
[TBL] [Abstract][Full Text] [Related]
15. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial.
Maeng M; Tilsted HH; Jensen LO; Krusell LR; Kaltoft A; Kelbæk H; Villadsen AB; Ravkilde J; Hansen KN; Christiansen EH; Aarøe J; Jensen JS; Kristensen SD; Bøtker HE; Thuesen L; Madsen M; Thayssen P; Sørensen HT; Lassen JF
Lancet; 2014 Jun; 383(9934):2047-2056. PubMed ID: 24631162
[TBL] [Abstract][Full Text] [Related]
16. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schömig A; Kastrati A
Eur Heart J; 2009 Apr; 30(8):923-31. PubMed ID: 19240066
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
[TBL] [Abstract][Full Text] [Related]
18. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 3-year clinical outcomes between Resolute™ zotarolimus- and sirolimus-eluting stents for long coronary artery stenosis.
Im E; Kim BK; Ko YG; Her AY; Choi HH; Shin DH; Kim JS; Choi D; Jang Y; Hong MK
J Interv Cardiol; 2013 Aug; 26(4):378-83. PubMed ID: 23844852
[TBL] [Abstract][Full Text] [Related]
20. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
Harada Y; Colleran R; Kufner S; Giacoppo D; Rheude T; Michel J; Cassese S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
Cardiovasc Diabetol; 2016 Sep; 15(1):124. PubMed ID: 27586678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
